Furthermore, the crosstalk between the Hh pathway and other signaling networks, such as the PI3K/AKT and MAPK pathways, highlights the potential for Itraconazole to synergize with other therapeutic strategies, such as BRAF inhibitors or immune checkpoint inhibitors, to overcome resistance mechanisms in melanoma treatment. The gene discussed is AKT1; the disease is melanoma.